Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for cancer. Due to the mechanism of action of ICIs, inflammatory reactions against normal tissue were an anticipated side effect of these agents; these immune-related adverse events have been documented and are typically low grade and manageable. Myocarditis has emerged as an uncommon but potentially life-threatening adverse reaction in patients treated with ICIs. Assessment and characterization of ICI-associated myocarditis is challenging because of its low incidence and protean manifestations. Nevertheless, the seriousness of ICI-associated myocarditis justifies a coordinated effort to increase awareness of this syndrome, identify patients who may be at risk, and enable early diagnosis and appropriate treatment. The “Checkpoint Inhibitor Safety Working Group,” a multidisciplinary committee of academic, industry, and regulatory partners, convened at a workshop hosted by Project Data Sphere, LLC, on December 15, 2017. This meeting aimed to evaluate the current information on ICI-associated myocarditis, determine methods to collect and share data on this adverse reaction, and establish task forces to close the identified knowledge gaps. In this report, we summarize the workshop findings and proposed steps to address the impact of ICI-associated myocarditis in patients with cancer. The Oncologist 2018;23:874–878

Myocarditis has recently emerged as an uncommon adverse reaction in patients administered ICIs, as noted in case reports [6–26], clinical trials [27–30], safety databases [14, 31, 32], and registries [33]. Due to the low incidence of ICI-associated myocarditis, data on presentation, diagnosis, treatment, and outcomes are limited [33, 34]. Nevertheless, preliminary clinical experience indicates ICI-associated myocarditis can be life threatening and therefore warrants efforts to increase awareness, identify patients who may be at risk, facilitate early diagnosis, and develop effective treatments.

The impact of ICI-associated myocarditis is expected to grow as ICIs are evaluated in patients with earlier-stage cancer with a higher likelihood of long-term survival, as well as in combination regimens, which appear to carry an increased risk of myocarditis [14, 33]. In 2015, an estimated 600,000 patients with metastatic cancer in the U.S. were eligible for ICI treatment [35]. This number is anticipated to increase across all
In 2017, there were 940 immuno-oncology agents being tested in 3,042 clinical trials with a target enrollment of 577,076 patients [36].

Evaluation of ICI-associated myocarditis in clinical trials is challenging because the number of patients who develop myocarditis in any single study or group of studies is likely too small to establish risk factors, screening guidelines, diagnostic criteria, or optimal management. Thus, coordinated efforts are urgently needed to better characterize ICI-associated myocarditis. Accordingly, the U.S. Food and Drug Administration (FDA) hosted a public workshop on December 1, 2017, to discuss cardiovascular toxicities in immuno-oncology clinical trials [37].

A multidisciplinary committee assembled on December 15, 2017, for an ICI-associated myocarditis workshop hosted by Project Data Sphere, LLC, an independent, nonprofit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium [38, 39]. Representatives of key stakeholders from academia, industry, and regulatory agencies, including the U.S. and China FDAs and the European Medicines Agency (collectively, the “Checkpoint Inhibitor Safety Working Group”), convened to review the existing, albeit limited, information on ICI-associated myocarditis; identify optimal ways to collect and share data; establish cross-functional teams to develop a case definition, diagnostic work-up, and treatment algorithms; and delineate research priorities (Fig. 1).

**Figure 1.** Checkpoint Inhibitor Safety Working Group meeting and goals.

Based on published accounts [6–26, 32, 33] and ~150 cases reviewed at the workshop, the clinical presentation of ICI-associated myocarditis may be quite variable. Manifestations range from nonspecific symptoms that may be erroneously attributed to underlying disease (e.g., fatigue, chest pain, dyspnea) to acute arrhythmias, conduction disorders, clinical heart failure, and sudden death. ICI-associated myocarditis may occur alone or in the setting of irAEs involving other organs [11], especially muscles (myositis) [14, 15, 27, 29, 31, 32].

There are no universally accepted criteria for a diagnosis of ICI-associated myocarditis, but position statements [41] and clinical practice guidelines [42] for myocarditis due to other causes provide benchmarks. Inexpensive and widely available tests used for diagnosing ICI-associated myocarditis include troponin measurements and electrocardiograms [7, 10, 12–15, 19, 20, 22]. However, these tests lack the sensitivity and specificity for a definitive myocarditis diagnosis. Additional standard imaging methods that have been used for the assessment and diagnosis of ICI-associated myocarditis include echocardiography and cardiac magnetic resonance imaging, which may reveal

---

**Current Knowledge**

The first specific report of myocarditis during treatment with a PD-1/PD-L1 inhibitor was published in 2014 [27], and a number of cases of ICI-associated myocarditis have been described since [6–26]. In an early analysis of more than 20,000 patients treated with ICIs, either alone or in combination, the incidence of myocarditis was 0.09%; the incidence of fatal myocarditis in this sample was 0.03% [14]. A recent study identified 101 cases of severe ICI-associated myocarditis in the World Health Organization global database of more than 16 million individual case safety reports (VigiBase) [40] and found reporting of cases increased substantially over time (3 in 2010–2014, 6 in 2015, 15 in 2016, and 76 in 2017) [32]. The true incidence of ICI-associated myocarditis may be underestimated due to the wide range of clinical presentations, challenges in diagnosis, and a general lack of awareness of this condition.

ICI-associated myocarditis appears to be a class effect, and the risk of myocarditis seems to be higher when these drugs are administered in combination regimens [14, 33]. An analysis of a multicenter registry found that combination ICI treatment was more common in patients with ICI-associated myocarditis compared with a random sample of ICI-treated patients without myocarditis (34% vs. 2%; p < .001) [33]. This is an important consideration as ICI combinations become a focus of immuno-therapy development [36]. To date, most reported cases of myocarditis have occurred in patients receiving single-agent ICI therapy, possibly reflecting the preponderance of clinical trial data and clinical experience with ICIs administered in this manner.

Based on published accounts [6–26, 32, 33] and ~150 cases reviewed at the workshop, the clinical presentation of ICI-associated myocarditis may be quite variable. Manifestations range from nonspecific symptoms that may be erroneously attributed to underlying disease (e.g., fatigue, chest pain, dyspnea) to acute arrhythmias, conduction disorders, clinical heart failure, and sudden death. ICI-associated myocarditis may occur alone or in the setting of irAEs involving other organs [11], especially muscles (myositis) [14, 15, 27, 29, 31, 32].
left-ventricular ejection fraction abnormalities, wall motion abnormalities, myocardial edema, and fibrosis. Even endomyocardial biopsy, currently considered the gold-standard method for diagnosis, has its limitations, as ICI-associated myocarditis may occur as a patchy distribution of T-cell-predominant lymphocytic infiltrate within or adjacent to regions of myocardial necrosis [7, 11, 13, 19, 20, 23], similar to histologic findings in patients with cardiac transplant rejection [14]. Therefore, proper diagnosis of ICI-associated myocarditis may involve a combination of high clinical acumen, biomarkers, cardiac imaging, and endomyocardial biopsy.

Like most iAEs, which typically emerge early in the course of treatment [1], preliminary observations suggest ICI-associated myocarditis generally occurs within 3 months of treatment initiation [7, 9–11, 13–15, 18–20, 22–24]. Management of ICI-associated myocarditis varies in published reports but frequently includes administration of corticosteroids [7, 9–15, 19, 20, 22–26], with outcomes ranging from complete resolution to the occurrence of major adverse cardiac events and/or death.

**Monitoring Guidelines**
Consensus guidelines for monitoring myocarditis in clinical studies of ICIs are needed. Closer monitoring may be appropriate for trials in the adjuvant or neoadjuvant setting, combination ICI regimens, and coadministration of ICIs with other agents with known cardiovascular toxicities. In large phase III trials, it may be valuable to screen patients for potential risk factors for ICI-associated myocarditis, for example, pre-existing cardiac dysfunction or autoimmune disease, and monitor patients with and without these characteristics for prospective efficacy and safety comparisons.

**Risk Factors and Pathogenesis**
Although unknown at present, risk factors for ICI-associated myocarditis may include genetic variants associated with innate or adaptive immunity. It may be possible to analyze existing biospecimens from clinical trials to identify potential germline genetic factors and/or circulating biomarkers for the diagnosis and prognosis of ICI-associated myocarditis. Consideration should be given to collection of specific biospecimens in clinical trials for subsequent large-scale genomic and proteomic analyses.

The basic pathophysiology of ICI-associated myocarditis requires further elucidation. Existing data indicate myocarditis is characterized by intense infiltration of T lymphocytes and macrophages [7, 11, 13, 14, 19, 20, 23]. Preliminary evidence suggests common high-frequency T-cell receptor sequences in infiltrates from the cardiac muscle and tumor, raising the possibility of a common (shared) epitope between the tumor and the heart [14]. The rapid onset of myocarditis following ICI treatment suggests the presence of a pre-existing factor and pathway (or autoimmune disease) that is held in check by the targeted pathogenesis and test potential treatments.

**Treatment Algorithms**
There is a clear need for a multidisciplinary team of oncologists, cardiologists, and other specialists to develop a standardized approach to the management of ICI-associated myocarditis. Initial recommendations have included consensus guidelines from the Society for Immunotherapy of Cancer Toxicity Management Working Group [4] and the American Society of Clinical Oncology (ASCO) in collaboration with the National Comprehensive Cancer Network (NCCN) [5]. These guidelines recommend consultation with a cardiologist, discontinuation of ICI therapy, and administration of high-dose corticosteroids (e.g., 1 mg/kg methylprednisolone) in cases of confirmed or suspected myocarditis [4, 5], in line with published findings [33]. The ASCO/NCCN panel also suggests that cardiac symptoms be managed per guidelines from the American College of Cardiology and American Heart Association in collaboration with a cardiologist [5]. Both groups acknowledge that due to limited data on ICI-associated myocarditis, their recommendations for management of this adverse reaction are based on anecdotal evidence [4, 5], and treatment guidelines are expected to evolve as more data on ICI-associated myocarditis are reported and assembled. Similar to the approach being used to generate a case definition, efforts are underway by workshop participants to assess published cases of ICI-associated myocarditis and propose management strategies.
CHARTING A PATH FORWARD: A CALL TO ACTION

Data Sharing
To facilitate robust investigations into ICI-associated myocarditis, the Checkpoint Inhibitor Safety Working Group supported the establishment of a single, integrated database of deidentified, patient-level data within Project Data Sphere, with industry sponsors, National Cancer Trial Network organizations, and high-volume cancer centers contributing to this repository. This approach is supported by the U.S. FDA Oncology Center of Excellence for the analysis of uncommon but clinically significant irAEs, including myocarditis [47]. As an open-access, data-sharing platform [39, 48], Project Data Sphere provides researchers with a venue to analyze large clinical datasets of ICI-treated patients that could provide a more accurate estimate of the true incidence of ICI-associated myocarditis, define its clinical characteristics, identify risk factors, and refine diagnostic and treatment algorithms. Future efforts could expand this framework to include ICI-associated myocarditis events observed in patients in the real-world setting.

Formation of Task Forces to Address Information Gaps
The workshop participants prioritized actions to close the information gaps for ICI-associated myocarditis and proposed three working groups to accomplish this: a Research Task Force to identify and prioritize research questions to guide analyses performed on data uploaded to Project Data Sphere; a Case Definition Task Force to establish diagnostic criteria and work-up algorithms; and an Education Task Force to develop treatment algorithms and instruct clinical trial investigators and treating physicians (Fig. 1).

CONCLUSION
ICIs hold tremendous promise for extending the lives of patients with cancer. As ICI use increases rapidly in clinical trial and real-world settings, it is critical to undertake efforts to mitigate the risk of uncommon but life-threatening adverse reactions, including myocarditis. The workshop convened by Project Data Sphere brought together academic, industry, and regulatory partners on short notice to share information, identify knowledge gaps, pose research questions, and initiate development of a case definition and approach to treatment for ICI-associated myocarditis, with the ultimate goal of minimizing the risk of this adverse reaction in patients with cancer who are treated with ICIs.

ACKNOWLEDGMENTS
Financial and organizational support for the December 15, 2017, ICI-associated myocarditis workshop was provided by Project Data Sphere, LLC; additional financial support was supplied by a grant from the Parker Institute for Cancer Immunotherapy. Medical writing support was provided by Joanna Bloom, Ph.D., of Engage Scientific Solutions, and was funded by Pfizer. We thank Patrick Caubel of Pfizer, Roland Chen of Bristol-Myers Squibb, William Holmes and Mayur Patel of AstraZeneca/MedImmune, Antonio Kwan of Genentech, and Kamal Shah of EMD Serono/Merck for their support in forming the Checkpoint Inhibitor Safety Working Group.

The Checkpoint Inhibitor Safety Working Group includes Hesham Abdullah (AstraZeneca/MedImmune), Laléh Amiri-Kordestani (U.S. Food and Drug Administration), Cecilia Bakker (Pfizer), Chris Boshoff (Pfizer), Charlie Brinjagh (Pfizer), Samantha Bucktrout (Parker Institute for Cancer Immunotherapy), Kathleen Carlin (Pfizer), Patrick Caubel (Pfizer), Roland Chen (Bristol-Myers Squibb), Kevin Chin (EMD Serono/Merck), Aleksander Chudnovsky (Pfizer), John Davis, Jr. (Pfizer), Jonathan Deutsch (Bristol-Myers Squibb), Rakesh Dixit (AstraZeneca/MedImmune), Christer Gottfridsdottir (AstraZeneca/MedImmune), William Gregory (Pfizer), Tarek A. Hammad (EMD Serono/Merck), Dave Handelsman (Project Data Sphere), Subramanian Harihara (Pfizer), William Holmes (AstraZeneca/MedImmune), Peter Honig (Pfizer), Charles Hugh-Jones (Pfizer), Howard Kaufman (Rutgers Cancer Institute of New Jersey), Nasir Khan (Pfizer), David Kozono (Harvard Medical School, Brigham and Women’s Hospital, Dana-Farber Cancer Institute), Antonia Kwan (Genentech), Freda C. Lewis-Hall (Pfizer), Sergio Ley-Acosta (Genentech), JoAnn Lindendief (Vanderbilt University), Elisabethe Michelon (Pfizer), Javid J. Moslehi (Vanderbilt University), Martin J. Murphy (Project Data Sphere), Tomas G. Neilian (Massachusetts General Hospital), Mayur Patel (AstraZeneca/MedImmune), Dejan Pavlovic (AstraZeneca/MedImmune), Francesco Pignatti (European Medicines Agency), Jonathan Potter (Pfizer), David Reese (Amgen), Mace L. Rothenberg (Pfizer), Allan Safferman (Pfizer), Eliza Silverste (Satori Consulting/Pfizer), Richard M. Steingart (Memorial Sloan Kettering Cancer Center), Ryan J. Sullivan (Massachusetts General Hospital), and Ming Zhou (China FDA).

DISCLOSURES
Tomas G. Neilian: Takeda (C/A); Mace L. Rothenberg: Pfizer (E); Ryan J. Sullivan: Merck; Novartis, Amgen (C/A); Merck, Amgen (RF); Richard M. Steingart: Pfizer (Data and safety monitoring board); William Gregory: Pfizer (E); Subramanian Harihara: Pfizer (E); Tarek A. Hammad: EMD Serono (E); JoAnn Lindendief: Novartis, Abbott, Edwards, VWave, CVRx, Relypsa, Resmed (C/A); AstraZeneca, Novartis (RF); Javid J. Moslehi: Pfizer, Novartis, Bristol-Myers Squibb, Takeda, Regeneron, Daichi Sankyo, Pharmacyclics (C/A); Pfizer, Bristol-Myers Squibb (RF). The other authors indicated no financial relationships.

REFERENCES
1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–168.
2. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 2016;375:1767–1778.
3. Rapoport BL, van Eeden R, Silbaud V et al. Supportive care for patients undergoing immunotherapy. Support Care Cancer 2017;25:3017–3030.
4. Puzanov I, Diab A, Abbildah K et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.
5. Brahmer JR, Lacchetti C, Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018 [Epub ahead of print].
6. Geisler BP, Raad RA, Eshai D et al. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: A case of takotsubo-like syndrome. J Immunother Cancer 2015;3:4.
7. Laubli H, Balmelli C, Bossard M et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11.

www.TheOncologist.com ©AlphaMed Press 2018
8. Koelzer VH, Rothschild SJ, Zihler D et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—An autopsy study. J Immunother Cancer 2016;4:13.
9. Mehta A, Gupta A, Hannallah F et al. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res 2017;27:155–158.
20. Gibson R, Delaune J, Szady A et al. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep 2016;2016.
11. Heinzler I, Ott PA, Hodi FS et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016;4:50.
12. Semper H, Muehlberg F, Schulz-Menger J et al. Drug-induced myocarditis after nivolumab treatment in a patient with PD-L1-negative squamous cell carcinoma of the lung. Lung Cancer 2016;99:117–119.
13. Tadokoro T, Keshino E, Makiya A et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail 2016;9.
14. Johnson DB, Balko JM, Compton ML et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755.
15. Behling J, Kees J, Munafi T et al. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 2017;27:155–158.
16. Berg DD, Vaduganathan M, Nohria A et al. Immune-related fulminating myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukemia. Eur J Heart Fail 2017;19:682–685.
17. Reuben A, Petacca de Macedo M, McCuaide J et al. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 2017;6:e1361097.
18. Matson DR, Azzola MA, Rehruan WM et al. Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci 2018;63:954–957.
19. Fukasawa Y, Sasaki K, Natsume M et al. Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol 2017;10:809–812.
20. Tay RV, Blackley E, McLean C et al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 2017;117:921–924.
21. Arangalage D, Delyon J, Lemmreux M et al. Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 2017;167:683–684.
22. Chen Q, Huang DS, Zhang LW et al. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol (Phila) 2017 (Epub ahead of print).
23. Norwood TG, Westbrook BC, Johnson DB et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 2017;5:51.
24. Nasr F, El Rasy E, Maalouf G et al. Severe ortho- nolimpopelonea and myocarditis following the administration of pembrolizumab. Eur J Cancer 2018;91:171–173.
25. Tajmir-Riahi A, Bergmann T, Schimid M et al. Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother 2018;41:35–38.
26. Frigeri M, Meyer P, Banfi C et al. Immune checkpoint inhibitor-associated myocarditis: A new challenge for cardiologists. Can J Cardiol 2018;34:92.e1–92.e3.
27. Heery CI, Coyne GH, Madan RA et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-1 monoclonal antibody, in advanced solid malignancies. J Clin Oncol 2014;32(suppl):3064a.
28. Egermont AM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522–530.
29. Balar AV, Castellano D, O’Donnell PH et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced or unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 3 trial. Lancet Oncol 2018;19:1483–1492.
30. Ngheim PT, Bhatia S, Lipson EU et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016;374:2542–2552.
31. Suzuki S, Ishikawa N, Konoeda F et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017;89:1127–1134.
32. Mosleh JJ, Salem JE, Jossum JA et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933.
33. Mahmood SS, Fralley MG, Cohen JV et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755–1764.
34. Escudier M, Cautela J, Malissen N et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 2017;136:2085–2087.
35. Andrews A. Treating with checkpoint inhibitors—figure $1 million per patient. Am Health Drug Benefits 2015;8 (Spec Issue):9.
36. Tang J, Shalabi A, Hubbard-Lucy VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 2018;29:84–91.
37. U.S. Food and Drug Administration. FDA Public Workshop: Assessment of cardiovascular toxicities in immuno-oncology trials. 2017 (last update: December 1, 2017). Available at https://www.fda.gov/Drugs/NewsEvents/ucm574741.htm. Accessed March 8, 2018.
38. Project Data Sphere, LLC. Available at www. ProjectDataSphere.org. Accessed March 12, 2018.
39. Bertagnolli MM, Sartor O, Chabner BA et al. Advantages of a truly open-access data-sharing model. N Engl J Med 2017;376:1178–1181.
40. Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring. VigiBase. 2018. Available at https://www.who-umc.org/vigibase/vigibase/. Accessed April 2, 2018.
41. Caforio AL, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–2648, 2648a–2648d.
42. Sinagra G, Anzini M, Pereira NL et al. Myocardi- tis in clinical practice. Mayo Clin Proc 2016;91:1256–1266.
43. Seko Y, Yagita H, Okumura K et al. Roles of pro- grammed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsakievirus B3. Cardiovasc Res 2007;75:158–167.
44. Lucas JA, Menke J, Rabacal WA et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol 2008;181:2513–2521.
45. Wang J, Okazaki IM, Yoshida T et al. PD-1 defi- ciency results in the development of fatal myocardi- tis in MRL mice. Int Immunol 2010;22:443–452.
46. Tarrio ML, Grabie N, Bu DX et al. PD-1 protects against inflammatory and myocyte damage in T cell-mediated myocarditis. J Immunol 2012;188:4876–4884.
47. U.S. Food and Drug Administration, Oncology Center of Excellence. Letter of support for Project Data Sphere, LLC. (last update: April 19, 2017). Available at https://www.fda.gov/downloads/aboutfda/ centersoffices/officeofmedicalproductsandbiologics/ucm557557.pdf. Accessed March 12, 2018.
48. Green AK, Reeder-Hayes KE, Corte RV et al. The project data sphere initiative: Accelerating can- cer research by sharing data. The Oncologist 2015; 20:464–e20.

©AlphaMed Press 2018